This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George A. Keepers, MD; Valerie J. Clappison, MD; Daniel E. Casey, MD

Arch Gen Psychiatry. 1983;40(10):1113-1117.

Abstract
• Initial prophylaxis with anticholinergics for neurolepticinduced extrapyramidal syndromes (EPSs) is controversial. Recommendations, based on conflicting research findings, vary from routine prophylactic use of anticholinergics to withholding these agents until dystonia, akathisia, or parkinsonism develops. To determine whether anticholinergic prophylaxis influenced EPS rates during the first 21 days of neuroleptic treatment, 215 psychotic inpatients were reviewed. Initial prophylaxis with anticholinergic drugs significantly reduced the occurrence of EPSs. This treatment's efficacy depended on a complex interaction of variables, including the patient's sex and age, antipsychotic drug type and dose, and treatment phase.

Author Affiliations
From the Departments of Psychiatry (Drs Keepers, Clappison, and Casey) and Neurology (Dr Casey), School of Medicine, Oregon Health Sciences University, and Medical Research, Psychiatry, and Neurology Services (Dr Casey), Veterans Administration Medical Center, Portland.

Footnotes
Accepted for publication Sept 22, 1982.

Reprint requests to Psychiatry Service, Veterans Administration Medical Center, Portland, OR 97207 (Dr Casey).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia
Findling et al.
Am. J. Psychiatry 2008;165:1432-1441.
ABSTRACT | FULL TEXT  

Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
Sikich et al.
Am. J. Psychiatry 2008;165:1420-1431.
ABSTRACT | FULL TEXT  

References
APPI Online CME 2007;2007:2-2.
FULL TEXT  

Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome
White
Journal of Pharmacy Practice 2005;18:175-187.
ABSTRACT  

Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Rosenheck
Psychiatr. Serv. 2005;56:85-92.
FULL TEXT  

Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials
Chakos et al.
Focus 2004;2:111-121.
ABSTRACT | FULL TEXT  

Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
Rosenheck et al.
JAMA 2003;290:2693-2702.
ABSTRACT | FULL TEXT  

Low dose typical antipsychotics - a brief evaluation
Taylor
Psychiatr. Bull. 2000;24:465-468.
FULL TEXT  

Fortnightly review: Acute dystonia induced by drug treatment
van Harten et al.
BMJ 1999;319:623-626.
FULL TEXT  

Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra et al.
Arch Gen Psychiatry 1996;53:1090-1097.
ABSTRACT  

Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT  

Haloperidol Blood Levels and Clinical Effects
Volavka et al.
Arch Gen Psychiatry 1992;49:354-361.
ABSTRACT  

Optimal Dose of Neuroleptic in Acute Schizophrenia: A Controlled Study of the Neuroleptic Threshold and Higher Haloperidol Dose
McEvoy et al.
Arch Gen Psychiatry 1991;48:739-745.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT